{"id":"lcb01-0371-800mg-bid","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"LSD1 is an epigenetic enzyme that removes activating histone marks, allowing cancer cells to silence tumor suppressor genes. By inhibiting LSD1, LCB01-0371 restores expression of genes critical for differentiation and apoptosis, particularly in acute myeloid leukemia and other hematologic malignancies. This epigenetic mechanism differs from traditional cytotoxic chemotherapy and may overcome certain drug resistance pathways.","oneSentence":"LCB01-0371 is a selective inhibitor of lysine-specific demethylase 1 (LSD1) that restores gene expression silenced by aberrant histone methylation in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:41:50.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Myelodysplastic syndrome (MDS)"}]},"trialDetails":[{"nctId":"NCT02836483","phase":"PHASE2","title":"A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK","status":"COMPLETED","sponsor":"LigaChem Biosciences, Inc.","startDate":"2016-12-10","conditions":"Pulmonary Tuberculosis","enrollment":79},{"nctId":"NCT02540460","phase":"PHASE1","title":"Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371","status":"COMPLETED","sponsor":"LigaChem Biosciences, Inc.","startDate":"2014-06","conditions":"Healthy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LCB01-0371"],"phase":"phase_2","status":"active","brandName":"LCB01-0371 800mg, BID","genericName":"LCB01-0371 800mg, BID","companyName":"LigaChem Biosciences, Inc.","companyId":"ligachem-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LCB01-0371 is a selective inhibitor of lysine-specific demethylase 1 (LSD1) that restores gene expression silenced by aberrant histone methylation in cancer cells. Used for Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}